In the rapidly evolving landscape of AI, pharma companies often rush to implement AI solutions without first clearly defining the problems they are trying to solve. This approach leads to misaligned initiatives that fail to deliver meaningful results as the focus is often too much on the “how” rather than the “why.”During this session Raj Madan, SVP and Chief Digital and Information Technology Officer, Arcutis Biotherapeutics, Inc., delves into the complexities and common pitfalls that organizations encounter on their AI journey, showcasing how in the fast-evolving world of AI, delivery is the currency of credibility.

Key discussion points include:

• Organizational Readiness: Learn how pharma companies can assess their readiness for AI adoption. This includes evaluating if they have the right culture, executive sponsorship and talent in place.
• Data Quality and Governance: AI is only as good as the data it’s fed. Discuss how Pharma companies must analyse their data to ensure it is fit for purpose
• Technology and Partnerships: Explore how pharma companies must consider partnership models, leveraging external expertise to accelerate AI adoption.

As AI continues to revolutionise healthcare, critical questions remain about its global impact, accessibility, and long-term market sustainability. Despite rapid advancements, no AI-discovered drug has yet passed Phase 3 clinical trials—how close are we to this breakthrough, and what challenges must be overcome?This closing panel brings together leading experts to explore the future of AI-driven therapeutics, the evolving biotech-pharma relationship, and strategies for ensuring equitable access to AI-powered healthcare innovations.

Key topics include:

• The Road to AI Drug Approval: What hurdles remain before AI-discovered drugs reach the market?

• Funding & Investment: How can we secure sustainable funding for AI-driven drug development?

• Bridging the Accessibility Gap: Ensuring AI-powered healthcare benefits reach global populations